An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu in Asian Patients with Allergic Rhinitis.

BACKGROUND

Allergic rhinitis (AR) is highly prevalent in Asia, but limited data exist on the real-world effectiveness of MP-AzeFlu (azelastine/fluticasone combination nasal spray) in Asian populations.

OBJECTIVE

To evaluate the real-world effectiveness of MP-AzeFlu in Asian patients with moderate-to-severe AR.

METHODS

This prospective, multicenter, noninterventional study enrolled patients with moderate-to-severe AR in Thailand, Taiwan, Malaysia, and Hong Kong. The patients received MP-AzeFlu and completed visual analog scale (VAS) assessments for AR symptoms over 28 days. The primary outcome was the proportion of responders (VAS score < 50 mm at least once during follow-up).

RESULTS

Of the 916 patients included in the safety population, 329 (35.92%) were males and 587 (64.08%) were females. Significant improvements were observed in the overall AR and nasal and ocular symptoms from day 1 through day 28 (p < 0.0001 for all). Asthma symptoms improved significantly in patients with comorbid asthma (11.7%), and 60% reduced use of asthma reliever medication was reported. Quality of life measures, including sleep quality and daily activities, also improved significantly. MP-AzeFlu was well-tolerated, with only six patients reporting mild adverse events.

CONCLUSIONS

In this real-world study, MP-AzeFlu provided rapid and sustained improvement in AR symptoms and quality of life in Asian patients with moderate-to-severe AR. MP-AzeFlu has also shown beneficial effects in patients with comorbid asthma. These results support the effectiveness of MP-AzeFlu in AR management in Asian populations.